EDGAR Filing Documents for 0000897069-04-001263

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0000897069-04-001263

Filing Date

2004-06-30

Accepted

2004-06-30 14:00:09

Documents

Period of Report

2003-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT	cmw777.htm	20-F	1006487
2	LIST OF SUBSIDIARIES	cmw777a.htm	EX-99.8	760
3	CODE OF CONDUCT	cmw777b.htm	EX-99.11	177273
4	CERTIFICATION	cmw777c.htm	EX-99.12(A)	7137
5	CERTIFICATION	cmw777d.htm	EX-99.12(B)	7069
6	CERTIFICATION	cmw777e.htm	EX-99.13(A)	1725
7	CERTIFICATION	cmw777f.htm	EX-99.13(B)	1680
	Complete submission text file	0000897069-04-001263.txt		1204369

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 514-332-32

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 04890916
SIC: 2835 In Vitro & In Vivo Diagnostic Substances